Review
Copyright ©The Author(s) 2022.
World J Gastroenterol. Sep 28, 2022; 28(36): 5280-5299
Published online Sep 28, 2022. doi: 10.3748/wjg.v28.i36.5280
Table 1 Summary of liver-specific drug delivery platforms, including molecular composition, potential modifications, benefits, and limitations
Platform
Composition
Origin
Benefits
Limitations
Lipid-based
LiposomesLipidsSyntheticNon-immunogenic, non-toxic, modifiableHigh clearance by liver/spleen RES
ExosomesLipidsBiologicalEndogenous cargo (proteins, nucleic acids, etc.), but can add additional cargoNon-standardized isolation methods, potentially immunogenic
MicellesLipidsBiologicalNon-immunogenic, non-toxic, modifiableHigh clearance by liver/spleen RES
Non-lipid-based
Polymeric nanoparticlesPolymersSyntheticModifiable, capable of controlled drug releaseHigh clearance by liver/spleen RES, potentially immunogenic
Metallic nanoparticlesGold, silver, aluminum, zinc, iron, gadolinium, copper, rubidium, palladium, titaniumSyntheticModifiable, magnetic (iron), anti-microbial (copper, silver, titanium)Non-biodegradable and potentially cytotoxic, immunogenic, or allergenic
Ceramic nanoparticlesCarbon, silicon with metallic or non-metallic coreSyntheticModifiable, resistant to pH changePotentially cytotoxic or immunogenic, non-biodegradable or lowly biodegradable
Bacterial and viral
BacteriaBacterial cellsBiologicalSelf-propulsion, chemotaxis, on-site drug production, transfectionImmunogenicity, infection risk
Viral vectorsAAVs, HSVsBiologicalActive liver tropismImmunogenicity, toxicity, neutralizing antibodies